Galmed Pharmaceuticals Q2 2026 Earnings Report

Galmed Pharmaceuticals EPS Results

• Actual EPS: -$2.86
• Consensus EPS: -$3.12
• Beat/Miss: Beat by +$0.26
• One Year Ago EPS: N/A

Galmed Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Galmed Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 9/2/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Galmed Pharmaceuticals (NASDAQ:GLMD) is an Israeli clinical-stage biopharmaceutical company focused on developing treatments for liver and metabolic diseases. The company’s research has centered on nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease associated with fat accumulation and inflammation.

Galmed’s lead product candidate has been aramchol, an orally administered synthetic conjugate of a fatty acid and bile acid. The company has evaluated aramchol for its potential to reduce liver fat and fibrosis, or scarring, in patients with NASH and related conditions. Galmed has also explored additional applications and combination-treatment strategies involving metabolic and liver disorders.

Founded in Israel, Galmed has conducted research and clinical-development activities in Israel, the United States and other international markets through clinical trials and regulatory interactions. The company has historically been led by founder and longtime chief executive officer Allen Baharaff. Galmed’s development programs and corporate status have changed over time, so investors should consult the company’s latest regulatory filings for current information about its pipeline, operations and leadership.